Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

BACKGROUND: Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study was designed to evaluate activity and safety of nab-paclitaxel in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Cancer
Hauptverfasser: Gelsomino, Francesco, Tiseo, Marcello, Barbieri, Fausto, Riccardi, Ferdinando, Cavanna, Luigi, Frassoldati, Antonio, Delmonte, Angelo, Longo, Lucia, Dazzi, Claudio, Cinieri, Saverio, Colantonio, Ida, Sperandi, Francesca, Lamberti, Giuseppe, Brocchi, Stefano, Tofani, Lorenzo, Boni, Luca, Ardizzoni, Andrea
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7341887/
https://ncbi.nlm.nih.gov/pubmed/32346071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0845-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge